OptaBlate BVN Ablation: Candidates and Recovery
OptaBlate BVN ablation is a device-specific pathway for basivertebral nerve ablation (treating a nerve inside the spine bone) in carefully selected patients with vertebrogenic low back pain (pain thought to come from the spine bone itself). This page is the companion to the broader basivertebral nerve ablation guide. BVN ablation is performed only at a hospital or surgery center – never in the office.
Quick Answer: OptaBlate BVN Ablation
- OptaBlate BVN ablation is a device platform for basivertebral nerve ablation (treating a nerve inside the spine bone).
- FDA 510(k) clearance May 15, 2025; “cleared” is the accurate word – not the same as a new-drug approval.
- The cleared pattern includes chronic low back pain for at least six months. It also includes failed appropriate conservative care for at least six months. And it includes Modic Type 1 or 2 MRI changes from L3 through S1 that match the exam.
- Modic changes are necessary imaging support. They are not enough alone.
- Procedure setting: hospital or surgery center only – not an office procedure; many patients go home the same day.
- OptaBlate and Intracept target the same nerve with different instruments and radiofrequency (RF) protocols. No published head-to-head outcome trial proves one better.
- Most long-term BVN-ablation outcome evidence was generated with Intracept, not OptaBlate.
- Red flags (new weakness, bowel/bladder loss, saddle numbness, fever with worsening spine pain): 911 / ER.
“My MRI shows Modic changes. Is OptaBlate appropriate for me, and how is it different from Intracept?”
OptaBlate BVN ablation is a newer device platform for basivertebral nerve (BVN) ablation. It treats the same anatomical pain pathway as Intracept. Device clearance does not mean that every patient with Modic changes is a candidate. It also does not mean that one platform has been proven clinically superior.
OptaBlate BVN ablation uses an FDA-cleared system to perform basivertebral nerve ablation. It is for carefully selected patients with chronic vertebrogenic low back pain (pain thought to come from the spine bone). The procedure targets the basivertebral nerve inside selected vertebral bodies (spine bones) from L3 through S1.
This is the device-specific companion to the broader Basivertebral Nerve Ablation guide. The parent guide explains the diagnosis and treatment category. This page focuses on the OptaBlate platform, candidacy, procedure, recovery, and evidence limitations.
What Is the OptaBlate Procedure?
The OptaBlate BVN Intraosseous Nerve Ablation System is a Class II medical device. It is used to create a controlled heat lesion at the basivertebral nerve. This sensory nerve lies inside the vertebral body (spine bone). It can carry pain signals from damaged vertebral endplates (the top and bottom surfaces of the bone).
During the procedure, the physician uses fluoroscopic guidance (live X-ray). The goal is to enter the targeted vertebral body through the pedicle (the bony bridge into the spine bone). A controlled path is created toward the basivertebral nerve. The OptaBlate probe then delivers radiofrequency energy (carefully controlled heat) at the planned location.
The treatment does not remove a disc, repair an endplate, take pressure off a spinal nerve, fuse the spine, or leave a permanent implant. It interrupts a specific sensory pathway linked with vertebrogenic pain.
When Did OptaBlate Receive FDA Clearance?
The FDA issued 510(k) clearance for the OptaBlate BVN system on May 15, 2025. The system was cleared through a substantial-equivalence pathway. That is an FDA path that says the device is like an already cleared one. The predicate device was the Intracept Intraosseous Nerve Ablation System.
“FDA-cleared” is the accurate description.
A 510(k) clearance establishes substantial equivalence to a legally marketed predicate device. It is not the same process as approval of a new drug. It also does not prove that OptaBlate produces better clinical outcomes than Intracept.
What Type of Back Pain Does OptaBlate Treat?
OptaBlate is intended for vertebrogenic low back pain. This pain is thought to arise from damaged vertebral endplates and nearby vertebral marrow (bone marrow inside the spine bone). The signals travel through the basivertebral nerve.
The clinical pattern is usually mainly axial (centered in the low back) rather than leg-dominant. Patients may describe deep central lower-back pain. It often flares with sitting, bending forward, lifting, or moving from sitting to standing. This pattern can overlap with discogenic, facet, sacroiliac, and muscular pain. So symptoms alone are not diagnostic.
What Do Modic Type 1 and Type 2 Changes Mean?
Modic changes are MRI findings adjacent to a vertebral endplate:
- Modic Type 1: marrow changes commonly linked with edema (fluid) and inflammation.
- Modic Type 2: fatty replacement within the vertebral marrow next to the endplate.
The FDA-cleared indication for OptaBlate includes features consistent with Modic Type 1 or Type 2 changes from L3 through S1. Modic changes support the diagnosis. They do not prove that the endplate is the main pain source.
Who May Be a Candidate for OptaBlate?
A potential OptaBlate candidate generally has a combination of symptoms, MRI findings, and treatment history. One abnormal MRI phrase is not enough.
Features That Support Candidacy
- Predominantly axial (central) lower-back pain
- Pain lasting at least six months
- Not enough improvement after at least six months of appropriate conservative care
- Modic Type 1 or Type 2 changes at one or more levels from L3 through S1
- Symptoms and MRI findings that match in location
- No untreated diagnosis that better explains the main symptoms
- A medical and anatomical profile that allows safe access through the pedicle (transpedicular access)
Are Modic Changes Enough to Qualify?
No. Many patients have more than one potential source of low back pain. The actual MRI images should be reviewed with the pain pattern. The examination, prior treatment responses, and competing diagnoses matter too.
| More Consistent With Vertebrogenic (Bone-Source) Pain | Suggests Another or Additional Pain Source |
|---|---|
| Deep, central axial (midline) low back pain | Mainly electric or shooting pain below the knee |
| Pain worsened by sitting, bending or lifting | Progressive weakness or numbness in a nerve-map pattern (dermatomal) |
| Matching Modic Type 1 or Type 2 endplate changes | Leg pain or heaviness with walking from significant spinal narrowing (neurogenic claudication) |
| Persistent symptoms despite appropriate nonsurgical care | Strongly confirmed facet (small spine joint) or sacroiliac-joint pain |
| No alternative diagnosis better explains the symptoms | Fracture, infection, tumor or substantial instability |
When OptaBlate May Not Be the Right Treatment
OptaBlate is not a general treatment for every abnormal lumbar MRI or every form of chronic low back pain. It does not directly treat pain caused mainly by:
- Facet-joint pain
- Sacroiliac-joint pain
- Classic radiculopathy (nerve-root pain) or sciatica from nerve-root compression
- Neurogenic claudication (leg pain or heaviness with walking) from lumbar spinal narrowing (stenosis)
- Symptomatic instability or high-grade spondylolisthesis (one bone slipped forward on another)
- New or unhealed vertebral compression fracture
- Active infection, tumor, or another destructive process in the spine bone
- Predominantly myofascial (muscle and soft-tissue) pain
- Hip disease or another non-spine condition
Some patients have mixed pain. A successful BVN procedure may improve the vertebrogenic part without eliminating pain from another structure.
How Does the OptaBlate Procedure Work?
The procedure is performed under fluoroscopic guidance (live X-ray). The physician advances an access cannula through the pedicle. Next comes a controlled curved path inside the vertebral body. Then the bipolar RF probe is placed at the planned basivertebral nerve target. Radiofrequency energy then creates a heat lesion meant to interrupt pain signals through the nerve.
The OptaBlate Procedure Pathway
Symptoms, actual MRI images, and competing pain sources are reviewed.
The physician advances a cannula through the pedicle under fluoroscopic guidance (live X-ray).
A curved access path allows the RF probe to reach the planned BVN target.
Controlled RF energy creates the planned heat treatment zone.
The patient is monitored, discharged, and followed as soreness settles and function changes.
What Is Different About the OptaBlate System?
According to Stryker and the FDA clearance summary, device features include:
- A bipolar radiofrequency (heat) probe
- A steerable curved introducer for placing the probe on target
- A Microinfuser that delivers saline to help manage tissue impedance (electrical resistance)
- A 10-gauge access system
- A manufacturer-specified 95 degrees C, seven-minute RF protocol
- A manufacturer-reported treatment zone of at least 1 cm under specified test conditions
- Multiple generator channels that can support treating more than one level at the same time when clinically appropriate
Technical features are not the same as proven clinical superiority.
A faster RF cycle, different probe, or larger manufacturer-tested lesion does not by itself prove better pain relief. It also does not prove better function or fewer complications. Those outcomes require comparative clinical evidence.
Anesthesia, Procedure Time and Discharge
Many basivertebral nerve ablation procedures are performed under general anesthesia. Selected patients may instead have the procedure with monitored anesthesia care, or MAC sedation. The choice is individualized. It depends on medical status, airway considerations, and tolerance of lying face-down (prone positioning). Anatomy, treatment duration, number of vertebral bodies, and the anesthesiology team’s judgment also matter.
Most patients are discharged the same day from the hospital or surgery center and need a responsible adult to drive them home. Follow the facility’s instructions about fasting, medication, driving, and activity.
Can OptaBlate Be Performed Under MAC Sedation?
Yes, in selected patients. Dr. Sharma has performed basivertebral nerve ablation under MAC sedation for more than two years. Avoiding general anesthesia may help some patients. It can avoid a breathing tube and certain general-anesthesia considerations. However, MAC is still anesthesia care. It has its own risks. It is not automatically safer or appropriate for every patient. The anesthesia team must remain prepared to deepen or convert the anesthetic if clinically necessary.
In Dr. Sharma’s experience, anesthesia teams often prefer to limit a MAC-sedation session to about three treated vertebral bodies. This matters. Three adjacent painful disc-endplate complexes (each painful disc with its bordering endplates) may require treatment of four vertebral bodies. For example, disease involving L3-4, L4-5, and L5-S1 may require BVN ablation at L3, L4, L5, and S1.
| Clinical Situation | Possible Practice Approach |
|---|---|
| One to three vertebral bodies treated under MAC | May be completed in one session when the patient and anesthesia plan are appropriate |
| Four vertebral bodies required using a longer workflow | May be divided into two staged visits to stay within the agreed MAC duration |
| Four vertebral bodies treated with OptaBlate | May sometimes be completed in one MAC session when patient factors and the anesthesia team permit |
Both OptaBlate and Intracept target the same basivertebral nerve. The choice is made with each patient based on anatomy and imaging. How many vertebral bodies are treated in one MAC-sedation visit depends on the anesthesia plan, access anatomy, and the procedural and anesthesia teams’ judgment – not on a claim that one device platform is easier or superior.
Neither system is presented here as better than the other. The choice is made with each patient.
No head-to-head clinical trial has established that OptaBlate is less traumatic, safer under MAC, or appropriate for more levels in one session. The decision to use MAC, general anesthesia, or staged treatment remains individualized. The procedural and anesthesia teams must agree on the plan.
Preparing for the OptaBlate Procedure
The treating team should review blood thinners (anticoagulants) and antiplatelet medication before the procedure. They also review diabetes, infection symptoms, allergies, pregnancy status, implanted electronic devices, and the anesthesia plan.
Do not stop aspirin, warfarin, or another blood thinner on your own.
Any pause must be coordinated with the prescribing clinician and procedural physician. The risk of bleeding must be balanced against the risk of stopping the medication.
Fasting and medication instructions depend on the anesthesia plan. The individualized instructions from the treating facility override general online information. Review the practice guide to planning for a procedure.
OptaBlate Recovery Time
OptaBlate BVN ablation is performed at a hospital or surgery center (not in the office). Most patients still go home the same day. Access through the pedicle and treatment inside the vertebral body can produce real postoperative soreness. Recovery instructions should be individualized rather than reduced to a one-size promise.
| Time After OptaBlate | What Patients May Experience | General Interpretation |
|---|---|---|
| Procedure day | Monitoring after anesthesia, incision soreness, and deeper aching near treated levels | A driver is required; follow discharge instructions |
| First several days | Local tenderness, muscle soreness, or a temporary increase in back pain | Early soreness does not decide the final result |
| One to two weeks | Many patients gradually resume ordinary daily activities | Work and lifting depend on symptoms and job demands |
| Several weeks | Some patients begin noticing improvement in familiar central (axial) pain and function | Check activity tolerance as well as pain score |
| Two to three months | Improvement may keep developing as activity and conditioning progress | A more useful interval for judging the overall response |
How Long Does OptaBlate Take to Work?
Improvement after basivertebral nerve ablation may develop gradually over several weeks and can continue over two to three months. Immediate relief is not required. Early procedural soreness should not be mistaken for treatment failure.
Meaningful outcome measures include improvement in the patient’s familiar central back pain. Sitting and standing tolerance, bending, and lifting matter too. So do sleep, work capacity, and ability to take part in rehabilitation.
When Should You Contact the Treating Team?
Contact the treating team promptly for severe or rapidly escalating pain. Also call for fever, chills, drainage, or increasing redness or swelling. New weakness, spreading numbness, loss of balance, bowel or bladder problems, and saddle-region numbness also need prompt contact. The same is true for any symptom that differs a lot from the expected recovery instructions.
What Evidence Supports OptaBlate?
The evidence must be separated into two categories:
- Device evidence: The FDA clearance summary documents OptaBlate’s engineering, performance testing, and substantial equivalence to Intracept.
- Clinical outcome evidence: Randomized trials and five-year follow-up support basivertebral nerve ablation in carefully selected patients. Those pivotal studies mainly evaluated the Intracept system.
As of August 2026, a published head-to-head clinical trial has not established that OptaBlate provides better pain relief, function, durability, or safety than Intracept. A prospective observational study of outcomes using the OptaBlate system is registered. Its results are not yet available.
What FDA substantial equivalence does and does not mean
The FDA concluded that OptaBlate has the same intended use as its predicate. It also found similar indications and technological characteristics. That supports legal marketing of the device. It is not a randomized comparison of patient outcomes.
OptaBlate vs Intracept: What Should Patients Know?
Both systems perform basivertebral nerve ablation. They target the same anatomical pain pathway. Their FDA-cleared indications are similar. The platforms differ in access instruments and probe design. They also differ in RF temperature and duration, and in how they manage impedance (electrical resistance).
The practical device choice should consider physician experience, target geometry, and anatomy. Equipment availability and an informed discussion of the evidence matter too. It should not be based only on a manufacturer’s claim about lesion size or treatment speed.
For the full technical and evidence comparison, read OptaBlate vs Intracept: Two Devices, One Nerve, No Head-to-Head Data. For the established Intracept patient pathway, see the Intracept procedure guide.
OptaBlate Risks and Limitations
Potential risks include:
- Temporary incision or procedural soreness
- Temporary increase in back pain
- Bleeding or hematoma (a pocket of blood)
- Infection
- Allergic or medication reaction
- Short-lived numbness, tingling, or weakness
- Injury to a nearby nerve or blood vessel
- Pedicle or vertebral (spine bone) injury
- Incomplete, temporary, or absent relief
- Anesthesia-related complications
- Need to evaluate or treat another pain source
Reasons not to proceed (contraindications) and precautions depend on current device labeling and anatomy. Infection status, pregnancy status, skeletal maturity, and medical fitness also matter. So do proximity to sensitive structures and implanted electronic devices. Final eligibility requires review of the current instructions for use and an individualized medical assessment.
OptaBlate does not repair the endplate, reverse disc degeneration, take pressure off a spinal nerve, correct instability, or guarantee permanent pain relief. A technically successful procedure cannot make up for an incorrect diagnosis.
Alternatives to OptaBlate
The appropriate alternative depends on the actual pain source and patient goals. Options may include:
- Diagnosis-specific physical therapy and graded conditioning
- Medication appropriate to the suspected pain mechanism
- The Intracept system or another suitable BVN-ablation platform
- Facet medial branch blocks and facet radiofrequency ablation for confirmed facet-mediated pain
- Epidural treatment for selected nerve-root (radicular) inflammation
- Sacroiliac-joint evaluation and treatment
- Minimally invasive decompression for qualifying spinal narrowing (stenosis)
- Endoscopic discectomy using the outside-in technique for selected lateral herniations, or conventional surgery when compression, instability, or another structural indication requires correction
- Continued observation when clinically safe and symptoms remain manageable
Failure of several prior treatments does not automatically prove vertebrogenic pain. The diagnostic match remains more important than the number of treatments already attempted.
Dr. Amit Sharma & our minimally invasive pain & spine team.
Frequently Asked Questions About OptaBlate
What is the OptaBlate procedure?
OptaBlate BVN ablation uses an FDA-cleared system to perform basivertebral nerve ablation. The physician accesses a selected lumbar vertebral body and uses radiofrequency energy to ablate the basivertebral nerve, which can carry pain signals from damaged vertebral endplates.
When should OptaBlate symptoms send you to emergency care instead?
OptaBlate is an elective procedure pathway, but back-pain red flags still matter at any stage. Call 911 or go to the nearest emergency room for new or progressive leg weakness, bowel or bladder loss, saddle-region numbness, fever with worsening spinal pain, or rapidly progressive neurologic change. Call SpinePain Solutions at 631-310-0000 for non-emergency questions.
Who may qualify for OptaBlate?
A potential candidate generally has predominantly axial low back pain lasting at least six months, inadequate improvement after at least six months of conservative care and Modic Type 1 or Type 2 changes from L3 through S1 that correspond to the clinical pain pattern. Other dominant pain generators must be considered.
Are Modic changes enough to qualify for OptaBlate?
No. Modic Type 1 or Type 2 changes support the diagnosis of vertebrogenic pain, but MRI findings alone do not prove that the vertebral endplates are the dominant pain generator. Symptoms, examination, treatment history and competing diagnoses must also fit.
Is OptaBlate FDA approved?
The OptaBlate BVN Intraosseous Nerve Ablation System received FDA 510(k) clearance on May 15, 2025. FDA-cleared is the accurate regulatory description.
Is OptaBlate the same as Intracept?
No. OptaBlate and Intracept are different device platforms used to perform the same treatment category: basivertebral nerve ablation. They share the same anatomical target and similar FDA-cleared indications, but their instruments and radiofrequency protocols differ.
Has OptaBlate been proven better than Intracept?
No published head-to-head clinical trial has established that OptaBlate produces better pain or functional outcomes than Intracept. OptaBlate received FDA clearance through substantial equivalence to Intracept, while most long-term basivertebral nerve ablation outcome data were generated using Intracept.
How long is recovery after OptaBlate?
Most patients are discharged the same day from the hospital or surgery center. Temporary incision soreness or deeper aching may occur, and activity is advanced according to the treating physician’s instructions. Return to work depends on soreness, job demands and the number of vertebral bodies treated.
Can OptaBlate be performed under MAC sedation instead of general anesthesia?
Yes, selected patients may undergo OptaBlate with monitored anesthesia care, or MAC, rather than general anesthesia. Dr. Sharma has performed basivertebral nerve ablation under MAC sedation for more than two years. The final anesthesia plan depends on medical status, airway considerations, prone positioning, treatment duration, number of vertebral bodies and the anesthesiology team’s judgment.
How long does OptaBlate take to work?
Improvement after basivertebral nerve ablation may develop gradually over several weeks and can continue over two to three months. Early procedural soreness should not be used to judge the final response.
Does OptaBlate treat sciatica or spinal stenosis?
OptaBlate does not decompress a spinal nerve or enlarge a narrowed spinal canal. It is not designed to treat classic radicular sciatica, progressive neurological loss or neurogenic claudication caused by spinal stenosis.
How do I find out if OptaBlate BVN ablation is right for me?
Bring your MRI images or disc (not just a summary line), a list of therapies already tried, your medication list, and notes on how sitting, bending, and standing change your central low back pain. At the visit we match your exam to the imaging, review competing pain sources, and decide whether basivertebral nerve ablation belongs in your plan and which hospital or surgery-center pathway fits. This page cannot decide candidacy for you.
Dr. Amit Sharma & our minimally invasive pain & spine team.
Related OptaBlate and Vertebrogenic Pain Resources
- Basivertebral Nerve Ablation: Parent Guide
- Vertebrogenic Pain
- Intracept Procedure
- OptaBlate vs Intracept
- Discogenic Pain
- Degenerative Disc Disease
- Diagnosing Back Pain
- Preparing for a Procedure
Dr. Amit Sharma & our minimally invasive pain & spine team.
References
- U.S. Food and Drug Administration. 510(k) Premarket Notification K250213: OptaBlate BVN Intraosseous Nerve Ablation System. Decision date May 15, 2025. Read source ->
- U.S. Food and Drug Administration. K250213 510(k) Summary: indications, device description and substantial-equivalence comparison. Read source ->
- Stryker. OptaBlate Basivertebral Nerve Ablation System: Product and Procedure Information. Read source ->
- Stryker. FDA Clearance Announcement for the OptaBlate BVN System. May 19, 2025. Read source ->
- Sayed D, Naidu RK, Patel KV, et al. Best Practice Guidelines on the Diagnosis and Treatment of Vertebrogenic Pain With Basivertebral Nerve Ablation From the American Society of Pain and Neuroscience. Journal of Pain Research. 2022;15:2801-2819. Read source ->
- Fischgrund JS, Rhyne A, Macadaeg K, et al. Long-Term Outcomes Following Intraosseous Basivertebral Nerve Ablation for the Treatment of Chronic Low Back Pain: Five-Year Treatment Arm Results. European Spine Journal. 2020;29(8):1925-1934. Read source ->
- Khalil JG, Truumees E, Macadaeg K, et al. Intraosseous Basivertebral Nerve Ablation: A Five-Year Pooled Analysis From Three Prospective Clinical Trials. Interventional Pain Medicine. 2024;3(4):100529. Read source ->
- ClinicalTrials.gov. Prospective Cohort Study of Outcomes Following Treatment With the Stryker OptaBlate BVN System. Read study record ->
- American Society of Anesthesiologists. Statement on Distinguishing Monitored Anesthesia Care From Moderate Sedation/Analgesia. Read source ->
About the Author
Amit Sharma, MD, Chief, Division of Pain Medicine at Good Samaritan University Hospital since 2012, is an interventional spine and pain-management physician. He performs basivertebral nerve ablation and other image-guided and minimally invasive spine procedures, including endoscopic discectomy using the outside-in technique for selected lateral herniations. He has clinical experience with both the OptaBlate and Intracept platforms. SpinePain Solutions evaluates candidates at Bay Shore, Commack and Farmingdale. Call or text 631-310-0000 (office locations).
Medical disclaimer: This page is educational and does not replace individualized medical evaluation, diagnosis or treatment. OptaBlate is not appropriate for every patient with chronic low back pain or Modic changes. Candidacy, preparation, anesthesia, risks, recovery instructions, device selection and facility pathway vary according to anatomy, medical history, diagnosis, facility requirements and current device labeling. Seek urgent medical attention for new weakness, bowel or bladder dysfunction, saddle-region numbness, fever with worsening spinal pain or rapidly progressive neurological changes.
